Drug pricing debate redux — should cost effectiveness analysis be used now to price pharmaceuticals?

New England Journal of Medicine

13 November 2021 - The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for negotiations: how to judge what’s a fair price. 

Absent well-functioning markets, cost effectiveness analyses can clarify the value that therapies deliver.

Read New England Journal of Medicine Perspective

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Pricing , Value